Subclinical Venous Injury in Transvenous Lead Extraction: Histological Correlation With Clinical Risk Factors
Journal of Cardiovascular Electrophysiology · 2026
DOI: 10.1111/jce.70402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Azalfa U Lateef und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA. Hauptthemen laut MEDLINE: Device Lead Extraction, Vascular System Injuries, Defibrillators, Implantable, Pacemaker, Artificial. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Transvenous lead extraction (TLE) is a commonly performed and generally safe procedure, though procedural complexity and risk can vary based on clinical and procedural factors.
Objective
This study aims to identify clinical and procedural factors associated with histologic evidence of subclinical vascular injury, defined by elastin positivity on extracted leads and its clinical significance.
Methods
Patients undergoing TLE with a lead dwell time of ≥ 1 year were included. Extracted leads with tissue were analyzed histologically using Verhoeff–Van Gieson staining to assess the presence of elastin. Demographic data, procedural and lead characteristics, and indication for extraction were obtained. Established extraction risk scores were calculated to determine efficacy in predicting subclinical vascular injury.
Results
The cohort included 49 patients with 92 leads extracted. A total of 25 patients (51%) had elastin‐positive leads. Complete procedural success occurred in 95.9% of cases. The multivariate regression model did not identify any independent predictors of elastin presence, including age (OR = 1.00; 95% CI 0.95–1.05; p = 0.89), female gender (OR = 3.04; 95% CI 0.67–13.65; p = 0.14), lead dwell time (OR = 1.13; 95% CI 0.98–1.29; p = 0.07). Additionally, no scoring system, such as the CCF, EROS, MB, SAFeTY, and LECOM, predicted the presence of elastin.
Conclusion
Subclinical venous injury was common following TLE, yet did not predict adverse clinical outcomes, reinforcing that TLE performed in experienced centers carries a favorable safety profile. Future studies in larger cohorts are needed to further characterize the clinical utility of subclinical vascular injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Cardiology, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Research, Mayo Clinic, Jacksonville, Florida, USA.
- Department of Pathology, Mayo Clinic, Jacksonville, Florida, USA.
- Electrophysiology & Cardiac Devices, Lee Health Heart Institute, Fort Myers, Florida, USA.
- Department of Cardiovascular Medicine, Division of Heart Rhythm, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Azalfa U Lateef, Ufuk Vardar, Aziza Nassar, Christoffel Van Niekerk, Fred Kusumoto, Danesh K Kella
Zitieren
APA
Lateef, A. U., Vardar, U., Hochwald, A., Nassar, A., Ladas, T., Chiriac, A., Niekerk, C. V., Kusumoto, F., & Kella, D. K. (2026). Subclinical Venous Injury in Transvenous Lead Extraction: Histological Correlation With Clinical Risk Factors. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70402
Vancouver
Lateef AU, Vardar U, Hochwald A, Nassar A, Ladas T, Chiriac A, et al. Subclinical Venous Injury in Transvenous Lead Extraction: Histological Correlation With Clinical Risk Factors. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70402
BibTeX
@article{Lateef2026,
author = {Lateef, Azalfa U and Vardar, Ufuk and Hochwald, Alex and Nassar, Aziza and Ladas, Thomas and Chiriac, Anca and Niekerk, Christoffel Van and Kusumoto, Fred and Kella, Danesh K},
title = {Subclinical Venous Injury in Transvenous Lead Extraction: Histological Correlation With Clinical Risk Factors},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2026},
doi = {10.1111/jce.70402}
}
EUVIMED